MRNA and MRK Related Headlines
Go Back- Moderna and Merck report sustained melanoma treatment benefits at 5 years
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
- US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Moderna and Merck report sustained melanoma treatment benefits at 5 years
- Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
- Vaccine stocks brace for shock waves at this week’s ACIP meeting
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
MRNA and MRK Related Press Releases
Go Back- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
- Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
